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The second meeting for the International Consensus on Antinuclear antibody (ANA) Pattern
(ICAP) was held on 22 September 2015, one day prior to the opening of the 12th Dresden
Symposium on Autoantibodies in Dresden, Germany. The ultimate goal of ICAP is to pro-
mote harmonization and understanding of autoantibody nomenclature, and thereby optimiz-
ing ANA usage in patient care. The newly developed ICAP website www.ANApatterns.org
was introduced to the more than 50 participants. This was followed by several presentations
and discussions focusing on key issues including the two-tier classification of ANA patterns
into competent-level versus expert-level, the consideration of how to report composite versus
mixed ANA patterns, and the necessity for developing a consensus on how ANA results
should be reported. The need to establish on-line training modules to help users gain compe-
tency in identifying ANA patterns was discussed as a future addition to the website. To
advance the ICAP goal of promoting wider international participation, it was agreed that
there should be a consolidated plan to translate consensus documents into other languages by
recruiting help from members of the respective communities. Lupus (2016) 25, 797–804.
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Introduction
The assay for antinuclear antibodies (ANA) is com-
monly used in the screening of autoantibodies in
systemic autoimmune diseases,1,2 and the indirect
immunoﬂuorescence assay utilizing HEp-2 cell sub-
strates remains the recommended methodology.3,4
HEp-2 cells grown as a semi-conﬂuent monolayer
exhibit prominent intracellular structures and is the
traditional ANA substrate of choice for most diag-
nostic laboratories. With appropriately equipped
microscopes, these features contribute to optimal
detection and ready recognition of many
subcellular structures. The International
Consensus on ANA staining Patterns (ICAP)
initiative originated as a session of the 12th
International Workshop on Autoantibodies and
Autoimmunity (IWAA) held in Sa˜o Paulo, Brazil,
in 2014. More than 60 participants took part in the
discussion during that meeting. The consensus
nomenclature and representative 28 patterns are
established and available on-line at the ICAP web-
site: www.ANApatterns.org.5 Patterns are categor-
ized into three major groups (nuclear, cytoplasmic,
and mitotic patterns) and each pattern has been
deﬁned and described in detail.5 The second
ICAP meeting was held a day prior to the 12th
Dresden Symposium on Autoantibodies in
Dresden, Germany on 23–26 September 2015.6
The present report summarizes the majority of
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issues discussed and the consensus initiatives for
future action. The ultimate goal of ICAP is to pro-
mote harmonization of autoantibody test nomen-
clature and interpretation, and to optimize ANA
usage in patient care.
The www.ANApatterns.org website and free
instructional posters
At the onset of the 2nd ICAP meeting, the
ANApatterns.org website was introduced by
Wilson deMelo Cruvinel (Brazil), who has been pri-
marily responsible for the development and oper-
ation of this website (Figure 1). Note that the
ANApatterns.org site is also formatted to be access-
ible onmobile devices including cell phones and tab-
lets. A general overview of the website was provided
and instructions for its use were included as an intro-
ductory chapter in the Proceedings of the Dresden
Symposium.6 Paulo Francescantonio and Marvin
Fritzler had previously commented that the actual
implementation of the ICAP recommendations by
diagnostic service laboratories would require ICAP
recommendations be taught to trainees and tech-
nologists at our respective institutions, and that
there needs to be persistence in presenting the cohe-
sive, consistent recommendation messages at both
national and international scientiﬁc symposia. In
keeping with these goals, additional items were
introduced to the website, including several free
Figure 1 An overview of the ICAP home webpage at www.ANApatterns.org. The web link A on the toolbar connects to the ICAP
nomenclature and classification tree (see Figure 2). Link B allows selection for nuclear, cytoplasmic, or mitotic patterns to provide
full descriptions. Link C provides selection from the list of all 28 alphanumeric coded patterns to access specific description and
images. Link D is the key word search function. Link E will access the website into selected languages still under construction. Link
F will access available free posters upon user registration. Link G provides access to ICAP publications.
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posters that are available upon user registration at
the website: http://anapatterns.org/download_ﬁ-
les.php. For example, one of the ﬁgures showing
the consensus nomenclature and the 28 patterns
are available for download as a full-size poster
(Figure 2). Additional slide sets to present the
ICAP patterns will be available in the future via
direct download from the website. These slide sets
will be useful for teaching purposes, for example.
The website had 14,288 page views from 19 May
to 11 September 2015. This represented a total of
more than 3000 visits from 94 countries within
these ﬁrst 4 months (25 visits/day). The top three
countries accessing the website during this period
were USA (21.80%), Brazil (12.13%), and
Germany (5.22%) (Figure 3(a)). The website
usage was mostly on personal computers (91.6%);
website usage on mobile cell phones and tablets was
7.61% and 0.76%, respectively (Figure 3(b)). This
preliminary access data is encouraging, and clearly
suggests that the ICAP website represents a useful
and acknowledged source of information.
Generally, comments for the ANApatterns.org
website have been highly positive regarding the
overall quality of the website. There were some
useful feedback comments. First, the number of
representative images per anti-cell (AC) pattern
provided at the initial setup for the website is lim-
ited to two. There were several requests to increase
the number of images for each pattern. Hence,
there are plans to obtain additional images that
will be evaluated and approved by a working com-
mittee as before. The record for each image will be
documented to indicate the source of images plus
other relevant information. Second, a suggestion
was made to provide an interpretive clinical
description for each AC pattern. This description
could be used as a standard comment to be
included in the ANA reports and there was a con-
sensus to move forward with this initiative. Third,
it was suggested to add a comment section on the
website to allow for comments from users. At a
later stage, potentially these comments may be
incorporated into a frequently asked questions
Figure 2 The nomenclature and classification tree for 28 HEp-2 cell patterns. The 28 ICAP patterns are designated with
alphanumeric AC code for each from AC-1 to AC-28. Boxes with amber background are recommended as competent-level
reporting, whereas those with olive green background are considered for expert-level reporting. AC, anti-cell.
International Consensus on ANA Patterns
EKL Chan et al.
799
Lupus
(FAQ) section of the website. This latter initiative
will be introduced in the coming year and will
involve members of the committee as well as
other interested groups.
Distinction of competent-level versus
expert-level patterns
In the ﬁrst ICAP report5 patterns were divided into
competent level versus expert level, with the inten-
tion that ANA readers should be trained to minim-
ally recognize all the patterns that are listed under
the competent level. Edward KL Chan (USA) and
Manfred Herold (Austria) were assigned to re-
address the issues regarding the decision on
which patterns are to be considered competent
level. Recommendations for clinical immunology
laboratories to become capable of reporting pat-
terns in the competent level include using available
standard sera, such as those of the IUIS/CDC
ANA standards, available from the Autoantibody
Standardization Committee via www.AutoAb.org,7
reference to images from the ICAP website at
ANApatterns.org,5 and use of additional subcellu-
lar markers (i.e. monoclonal antibodies) for co-
staining validations.
The classiﬁcation of patterns as competent level
did not follow strict criteria, but took into consid-
eration the clinical relevance and the morphological
consistency of the patterns. Some of the competent-
level patterns elicited further discussion at the
second ICAP meeting. The nuclear dense ﬁne
speckled pattern (AC-2) is considered particularly
important given its strong association with anti-
DFS70/LEDGF antibodies and the fact that
many investigators either have not heard of it or
do not know the relevance of its negative correl-
ation to systemic autoimmune rheumatic dis-
eases.8,9 There was some concern over the
apparent lack of clinical relevance of Golgi-like
pattern (AC-22)10–12 or the rods and rings pattern
(AC-23),13–16 and yet they represent distinctive and
consistent patterns that belong to the competent-
level group. It has been proposed that the compe-
tent level and expert level are equivalent to the
more simple description of ‘‘basic’’ and ‘‘advanced’’
levels and should not depend strictly on the clinical
relevance of the pattern. It should be stated that the
division between both levels may be considered
rather arbitrarily and most certainly can be chan-
ged in the future as new information is available. It
is acknowledged that users may not be considered
as ‘‘competent’’ versus ‘‘expert’’ based solely on the
ability to identify ANA patterns. Manfred Herold
brought up his concerns that a critical piece of
becoming ‘‘competent’’ in reading ANA is the abil-
ity to discriminate between positive and negative,
which is a topic worthy of further discussion on the
ICAP website and in subsequent ICAP meetings.
The concept of composite patterns as a separate
category did not reach consensus
Luis EC Andrade (Brazil) and Karsten Conrad
(Germany) were assigned to discuss whether certain
patterns should be considered ‘‘composite’’ pat-
terns. The discussion focused on how composite
patterns are deﬁned and the potential advantages
in adopting the ‘‘composite pattern’’ category.
Composite patterns would be deﬁned as those in
Figure 3 Summary of initial access to www.ANApatterns.org. A. Plot of countries with most visits to the website. B. Access of the
website categorized based on the type of device.
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which a single autoantibody speciﬁcity elicits the
staining of more than one cell compartment. For
example, NuMA (AC-26) may be considered a
‘‘composite’’ pattern because both nucleoplasmic
and mitotic spindle poles are stained, with the
implication that the staining in the two diﬀerent
compartments is characteristic of a single autoanti-
body speciﬁcity;17 in this example, anti-NuMA
monoclonal antibodies have shown the same stain-
ing pattern. One clear advantage of adopting the
category of composite patterns can also be illu-
strated by the NuMA pattern, as NuMA is classi-
ﬁed as a Mitotic Pattern in the ICAP classiﬁcation
tree despite the fact that all interphase cells show a
strong nucleoplasmic staining. Another rele-
vant advantage is the fact that the simultaneous
occurrence of a consistent set of features in the
composite patterns may increase the stringency of
association with the cognate autoantibody speciﬁ-
cities. In fact, the recognition of the multiple
features of the NuMA pattern is virtually pathog-
nomonic of anti-centrophilin/NuMA antibodies.
Other patterns that could be classiﬁed as composite
patterns include the CENP-F-like (AC-14), Scl-70-
like (not yet classiﬁed in the ICAP classiﬁcation
tree), and the peculiar cytoplasmic/nucleolar stain-
ing pattern associated with anti-ribosomal P anti-
bodies. The potential vulnerability for the category
‘‘composite pattern’’ is the confusion with ‘‘mixed’’
patterns as generated by sera that contain distinct
autoantibodies to diﬀerent antigens in diﬀerent
compartments. In addition, some specialists
noted the lack of necessity to assign a distinct
‘‘composite pattern’’ category, as the subcellular
localization of a given protein/antigen to diﬀerent
compartments at various stages of the cell cycle or
under diﬀerent physiological conditions is well
documented. In any case, no consensus was
obtained and it was decided that the category of
composite patterns will not be consented at this
time.
Caution on association of ANA patterns with
diseases
Minoru Satoh (Japan) and Jan Damoiseaux
(The Netherlands) were assigned to discuss the
advantages and limitations of ANA patterns in
relation to disease associations. For example, a
nucleolar pattern (AC-8–AC-10) is considered to
be associated with systemic sclerosis (SSc) primarily
because in this disease autoimmunity may be dir-
ected to several nucleolar antigens, like Th/To,18
U3-snoRNP/ﬁbrillarin, and PM-Scl.19 However,
the association between SSc and the nucleolar pat-
terns is very weak because the nucleolar pattern is
often observed, even in high titer, without any clin-
ical signs of SSc. It was further acknowledged that
a given ANA pattern should suggest what the tar-
geted autoantigens are in order to enable directed
reﬂex testing or appropriate advice to do so for the
clinician. It is the identiﬁcation of autoantibodies to
these self-antigens that are best associated to cer-
tain diseases, while the ANA patterns alone may be
insuﬃciently linked to these diseases. The centro-
mere pattern (AC-3) may be an exception, as this
pattern is strongly associated with reactivity
towards the CENP-B protein and, for that
reason, many laboratories do not perform any anti-
gen-speciﬁc testing for this pattern.20,21 However,
even in this case the association between the centro-
mere pattern and SSc is not absolute. Nevertheless,
the disease associations are primarily based on the
target antigens recognized by autoantibodies that
reveal a particular ANA pattern.5
Guideline for new patterns on the horizon
to be considered
Prior to the second ICAP meeting, members
assigned the speciﬁc task to focus on subcellular
compartments were asked to re-visit their topics
and provide an update for additional patterns to
be considered for inclusion in the future. Karsten
Conrad summarized ANA patterns that are asso-
ciated with the recently deﬁned myositis-speciﬁc
autoantibodies.22 Some of these autoantibodies do
not reliably reveal novel indirect immunoﬂuores-
cence (IIF) patterns and are ANA negative.4,23,24
Karsten Conrad also made a case to include a
more speciﬁc SS-A/Ro-like ANA pattern charac-
terized by a distinctive ﬁne speckled nuclear pattern
resembling a myriad of multiple nuclear dots.25 No
consensus was achieved regarding addition of these
patterns to the ICAP at this time.
Although there was no consensus on adding new
patterns to the existing 28 patterns from the ﬁrst
ICAP, it was agreed that guidelines are needed for
nomination and inclusion of novel patterns in the
future. There was little discussion due to time limi-
tation, but patterns associated with autoantibodies
with clinical relevance obviously should be con-
sidered a higher priority. Other ‘‘new’’ patterns
will need to await further documentation, as in
publications or otherwise, with well-deﬁned mar-
kers for validation.26–32 The availability of multiple
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consensus IIF images for new patterns is also
necessary.
An unresolved issue in ANA reporting
Jan Damoiseaux, Carlos A von Mu¨hlen (Brazil),
and Ignacio Garcia-De La Torre (Mexico) were
tasked to discuss how ANA reporting should
come to an international consensus. With respect
to the reporting of ANA, there was agreement that
the test result is to be reported as negative or posi-
tive, and if positive, the IIF pattern (according to
the ICAP nomenclature) and ﬂuorescence intensity
or titer are to be included. In addition, there was
consensus that the report should include informa-
tion on the test system applied, and, where appro-
priate, relevant contemporary literature provided
to the clinician; for example, the laboratory might
suggest that the test be repeated within a year or
sooner if clinical parameters change (i.e. if ANA is
at borderline positive). It was suggested that ICAP
may be a good platform for preparing clinical com-
ments to be added to the distinct patterns deﬁned.
There was no consensus as to whether cytoplas-
mic and mitotic patterns are to be reported as ANA
negative or positive, although it was widely agreed
that some cytoplasmic patterns are clinically rele-
vant and that this information should not be over-
looked. The major concern with respect to
reporting cytoplasmic patterns as ANA positive is
that, in some jurisdictions, existing guidelines and
diagnostic/classiﬁcation criteria are based on
restricting ANA to nuclear patterns. The most
striking example is the diagnostic criteria for auto-
immune hepatitis (1999), which is based on a scor-
ing system.33 A positive ANA, depending on the
titer, gives positive points, while the presence of
anti-mitochondrial antibodies requires subtraction
of points. This evidently results in a paradox if anti-
mitochondrial antibodies are reported as ANA
positive. A separate report has been compiled for
publication on the full discussion and proposals.34
On-line assessment for users to gain competence
in HEp-2 cell patterns
Edward Chan and Wilson de Melo Cruvinel lead
this discussion. It is acknowledged that training is
needed to ensure that all laboratories are able to
report patterns at the competent level (basic-level
training) as well as training to help advance all
laboratories to recognize expert-level patterns
(advanced-level training). It is clear that multiple
training programs already exist for ANA pattern
recognition and reporting. However, to date, none
has been adapted to the newly established ICAP
nomenclature or recommendations. The general
roadmap on ANA pattern training should be an
open system allowing diﬀerent groups to partici-
pate. Wilson de Melo Cruvinel has compiled a
draft proposal for an ICAP educational program
with a goal of developing an on-line assessment
tool for users to gain competence in ANA deter-
mination at both basic and advanced-level training.
For example, every 3 months, participants will
access the ICAP website restricted by password
login for the on-line immunoﬂuorescence images.
Users will examine the images provided and com-
plete analysis by ﬁlling out a form according to
ICAP guidelines. The users will be provided with
a quality assessment report, which will show (1) the
correct answers and results rated among the peer
group; (2) the detailed characterization of the pat-
tern; (3) autoantigen association and clinical rele-
vance. In the US and many other countries, the
program may be developed to provide Continuing
Education (CE) credits and perhaps an ICAP (or
IUIS/IWAA) certiﬁcate of competence. Yearly
refresher courses with CE credit may also be
considered.
Moving forward with ICAP internationalization
In order for ICAP to be recognized and be taken
full advantage of at an international level, continu-
ous improvement, extension, updating and main-
tenance of the ANApatterns.org site is essential.
In addition, translation into diﬀerent languages
will be necessary to further promote the eﬀort to
achieve general consensus. The discussion orga-
nized by Edward Chan, Ignacio Garcia-De La
Torre, and Wilson de Melo Cruvinel focused on
establishing a draft guideline for each language
translation project. To date, there are already pro-
jects on translation into German, Spanish, and
Portuguese. The guidelines consist of: (1) for each
language project, the translation should be handled
by a team rather than a single individual to pro-
mote acceptance and inclusion in daily practice; (2)
whenever appropriate, individuals from diﬀerent
countries sharing the same language should be
invited to participate; (3) at diﬀerent stages of the
process, potential users should be involved in a
‘‘beta test’’ of the draft translation. This may
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mean that it takes a longer time to achieve consensus
in translation, but it helps to spread the message
regarding the ICAP initiative. A draft letter to
‘‘recruit’’ members in the participation of translation
should introduce the general description of the ICAP,
the Frontiers Immunology publication5 and the
ANApatterns.org site; (4) further promotion is rec-
ommended. For example, the translation team may
consider planning a manuscript/report in regional/
local journals to announce the translated work. The
primary target audience should be clinical immun-
ology laboratories including organizations similar
to the American Medical Laboratory Immunology.
During the Dresden Symposium on
Autoantibodies, the issue of translation of the
ANApatterns.org was discussed at the European
Autoimmune Standardization Initiative (EASI) ses-
sion where it was generally agreed that the national
EASI teams35 will help with the translation of the
relevant European languages. This action also
enables to invite the national EASI teams for feed-
back on the content of the website.
Planning of future meetings
The ICAP executive members will meet again at the
time of the 10th International Congress of
Autoimmunity in Leipzig, Germany, where the
main agenda item will be the preparation for the
3rd ICAP meeting.
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